IQVIA Holdings Inc. $IQV Shares Sold by Crestwood Advisors Group LLC

Crestwood Advisors Group LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 10.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 117,465 shares of the medical research company’s stock after selling 14,169 shares during the period. Crestwood Advisors Group LLC’s holdings in IQVIA were worth $26,478,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after buying an additional 159,899 shares during the last quarter. Alliancebernstein L.P. increased its holdings in IQVIA by 1.2% in the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares in the last quarter. Boston Partners acquired a new stake in IQVIA in the 3rd quarter valued at $676,698,000. Artisan Partners Limited Partnership increased its holdings in IQVIA by 4.9% in the 3rd quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in IQVIA by 15.3% in the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after purchasing an additional 367,204 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE:IQV opened at $178.95 on Friday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a 50-day moving average of $170.14 and a two-hundred day moving average of $200.95. The stock has a market cap of $29.87 billion, a P/E ratio of 22.17, a PEG ratio of 1.75 and a beta of 1.18. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 11.5 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Stifel Nicolaus lowered their price target on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a report on Friday, February 6th. Truist Financial lowered their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and increased their price target for the company from $174.00 to $213.00 in a report on Monday, March 9th. Morgan Stanley set a $225.00 price target on IQVIA in a report on Thursday. Finally, Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, April 19th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.